PICTET BANK & TRUST Ltd acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 8,019 shares of the biopharmaceutical company’s stock, valued at approximately $291,000.
A number of other hedge funds also recently made changes to their positions in the business. HC Financial Advisors Inc. purchased a new position in Pfizer in the 4th quarter valued at about $2,685,000. Fiduciary Trust Co. boosted its position in Pfizer by 0.6% in the 1st quarter. Fiduciary Trust Co. now owns 555,624 shares of the biopharmaceutical company’s stock valued at $19,719,000 after buying an additional 3,316 shares during the last quarter. Bank of The West boosted its position in Pfizer by 0.7% in the 1st quarter. Bank of The West now owns 250,109 shares of the biopharmaceutical company’s stock valued at $8,876,000 after buying an additional 1,679 shares during the last quarter. Strategic Wealth Advisors Group LLC boosted its position in Pfizer by 134.7% in the 1st quarter. Strategic Wealth Advisors Group LLC now owns 216,803 shares of the biopharmaceutical company’s stock valued at $7,694,000 after buying an additional 124,420 shares during the last quarter. Finally, PM CAPITAL Ltd boosted its position in Pfizer by 5.1% in the 1st quarter. PM CAPITAL Ltd now owns 852,715 shares of the biopharmaceutical company’s stock valued at $30,263,000 after buying an additional 41,740 shares during the last quarter. Hedge funds and other institutional investors own 68.96% of the company’s stock.
A number of research firms have weighed in on PFE. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 27th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Goldman Sachs Group reissued a “neutral” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Wednesday, August 1st. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $42.67.
Shares of Pfizer stock opened at $44.28 on Friday. The stock has a market capitalization of $264.31 billion, a PE ratio of 14.90, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $45.81.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.03. The business had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.67 EPS. Sell-side analysts forecast that Pfizer Inc. will post 3 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.07%. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.
ILLEGAL ACTIVITY NOTICE: This report was first reported by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/10/pictet-bank-trust-ltd-takes-291000-position-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: When is a capital gain realized?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.